“The FDA’s Fast Track designation process is designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fill an unmet medical need. Immutep will now have access to more frequent interactions with the FDA to discuss efti’s development path and, if relevant criteria are met, eligibility for Rolling Review, Accelerated Approval, and Priority ReviewI”.
Important data due q4?
“The FDA’s Fast Track designation process is designed to...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
-0.015(4.55%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 32.5¢ | 31.0¢ | $1.029M | 3.271M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 51296 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |